Skip to main content
PharmaGraphX
PharmaGraphX
Log inGet Started

Important Disclaimer

PharmaGraphX is a research and educational tool only. It is NOT intended for clinical decision-making, patient care, or medical advice. All drug information, calculations, interactions, and recommendations are for educational and research purposes only. Always consult qualified healthcare professionals, official drug labeling (FDA, TGA, EMA), and institutional guidelines before making any clinical decisions. The developers assume no liability for any decisions made based on information provided by this platform.

© 2026 PharmaGraphX. All rights reserved.

|

For research and educational purposes only. Not medical advice.

Help
  • Navigate between workspaces using the left sidebar.
  • Use the main chat to ask any pharmacology question.
  • Press G then H to quickly navigate home.
Navigation
HomeG H
PK/PD StudioG P
Interaction HubG A
Digital TwinG T
Molecular LabG M

Press Esc to close

  1. Home
  2. /Database
  3. /Methotrexate

Methotrexate

Trexall, Otrexup, Rasuvo, Xatmep, Reditrex, Jylamvo

Antineoplastic • Antimetabolite / DMARD

Premium
NTIHepatotoxicNephrotoxic

Half-life

3-10 hours (dose-dependent)

Protein Binding

Metabolized By

N/A

External

Drugs.com

Mechanism of Action

Inhibits dihydrofolate reductase, blocking DNA and RNA synthesis

Indications(5)

Rheumatoid arthritis — first-line DMARDPsoriasis and psoriatic arthritisAcute lymphoblastic leukaemia (ALL)Non-Hodgkin lymphomaEctopic pregnancy

Classification

Drug Class

Antineoplastic

Subclass

Antimetabolite / DMARD

Brand Names

TrexallOtrexupRasuvoXatmepReditrexJylamvo

Key Properties

Half-life

3-10 hours (dose-dependent)

Time for plasma concentration to decrease by 50%

Protein Binding

—

Fraction bound to plasma proteins

Therapeutic Index

Narrow

Margin between therapeutic and toxic doses

Not a substitute for clinical judgement
Methotrexate Drug Profile | PharmaGraphX